Can ENTRESTO use pay-for-performance schemes and patient monitoring services to justify its anticipated budget impact in the U.S.?

Novartis’ recently approved ENTRESTO impressed regulators with stellar clinical outcomes, including a 20% reduction in the risk of cardiovascular death and hospitalization and a 16% improvement in overall survival compared to the standard-of-care ACE inhibitor therapy enalapril. ENTRESTO is expected to change the management of heart failure with reduced ejection…

AVASTIN in AMD: Justifying Discretionary Use and Reimbursement in FRA and ITA

Since the mid 2000s, GENENTECH / NOVARTIS’ LUCENTIS™ (ranibizumab) has enjoyed regulatory approval and funding across the USA and major EU markets for age-related macular degeneration (AMD). With strong efficacy and safety profiles as well first-to-market timing of marketing authorisation and funding, LUCENTIS is a presumptive market leader in the…